Expression of MAC30 in Rectal Cancers with or without Preoperative Radiotherapy

Oncology ◽  
2006 ◽  
Vol 71 (3-4) ◽  
pp. 259-265 ◽  
Author(s):  
Zhi-Yong Zhang ◽  
Zeng-Ren Zhao ◽  
Gunnar Adell ◽  
Ingvar Jarlsfelt ◽  
Yong-Xing Cui ◽  
...  
Keyword(s):  
Preoperative Radiotherapy ◽  
Rectal Cancers

277. Histology parameters and their variation with preoperative radiotherapy in rectal cancers

2014 ◽  
Vol 40 (11) ◽  
pp. S111
Author(s):  
S. Ionescu ◽  
E. Bratucu ◽  
B. Andreescu ◽  
A. Haidar ◽  
S. Zurac ◽  
...  
Keyword(s):  
Preoperative Radiotherapy ◽  
Rectal Cancers

Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203

2006 ◽  
Vol 24 (28) ◽  
pp. 4620-4625 ◽  
Author(s):  
Jean-Pierre Gérard ◽  
Thierry Conroy ◽  
Franck Bonnetain ◽  
Olivier Bouché ◽  
Olivier Chapet ◽  
...  
Keyword(s):  
Overall Survival ◽  
Acute Toxicity ◽  
Preoperative Radiotherapy ◽  
Rectal Adenocarcinoma ◽  
Digital Rectal Examination ◽  
Concurrent Chemotherapy ◽  
Sphincter Preservation ◽  
Moderate Increase ◽  
Operative Specimen ◽  
Rectal Cancers

Purpose In 1992, preoperative radiotherapy was considered in France as the standard treatment for T3-4 rectal cancers. The present randomized trial compares preoperative radiotherapy with chemoradiotherapy. Patients and Methods Patients were eligible if they presented a resectable T3-4, Nx, M0 rectal adenocarcinoma accessible to digital rectal examination. Preoperative radiotherapy with 45 Gy in 25 fractions during 5 weeks was delivered. Concurrent chemotherapy with fluorouracil 350 mg/m2/d during 5 days, together with leucovorin, was administered during the first and fifth week in the experimental arm. Surgery was planned 3 to 10 weeks after the end of radiotherapy. All patients should receive adjuvant chemotherapy with the same fluorouracil/leucovorin regimen. The primary end point of the trial was overall survival. Results A total of 733 patients were eligible. Grade 3 or 4 acute toxicity was more frequent with chemoradiotherapy (14.6% v 2.7%; P < .05). There was no difference in sphincter preservation. Complete sterilization of the operative specimen was more frequent with chemoradiotherapy (11.4% v 3.6%; P < .05). The 5-year incidence of local recurrence was lower with chemoradiotherapy (8.1% v 16.5%; P < .05). Overall 5-year survival in the two groups did not differ. Conclusion Preoperative chemoradiotherapy despite a moderate increase in acute toxicity and no impact on overall survival significantly improves local control and is recommended for T3-4, N0-2, M0 adenocarcinoma of the middle and distal rectum.

FBI-1 expression in relation to clinicopathological variables in rectal cancers with a Swedish clinical trial of preoperative radiotherapy.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e15102-e15102
Author(s):  
Chao-Jie Wang ◽  
Jian-Wei Zhou ◽  
Yun Zhou ◽  
Xiao-Feng Sun
Keyword(s):  
Clinical Trial ◽  
Rectal Cancer ◽  
Preoperative Radiotherapy ◽  
Disease Free Survival ◽  
Normal Mucosa ◽  
Tnm Stage ◽  
Nuclear Staining ◽  
Cytoplasmic Staining ◽  
Rectal Cancers ◽  
Pattern Differentiation

e15102 Background:FBI-1 is a recently characterized proto-oncoprotein of the POZ domain Krüppel-like (POK) family of transcription factors. Although several studies provide the evidence that FBI-1 is an important gene regulator in CRC, no analysis of any correlation between FBI-1 expression and preoperative radiotherapy (RT) has been studied in rectal cancers. Methods: This study included the patients with rectal cancer that participated in a Swedish clinical trial of preoperative RT between 1987 and 1990. Patients were divided into preoperative RT (62) and non-RT (77) groups. Applying immunohistochemstry, we detected FBI-1 expression in 118 normal mucosa, 139 primary rectal cancers, and 45 lymph node metastases, and analyzed its relationship with clinicopathological features and RT response. Results: FBI-1 was detected both in the cytoplasm and nucleus, and the cytoplasmic staining was up-regulated compared with normal mucosa both in non-RT and RT groups (74.0% vs. 17.7%, p < 0.001; 69.4% vs. 41.1%, p = 0.002), however, the nuclear staining was down-regulated compared with normal mucosa both in non-RT and RT groups (22.1% vs. 75.8%, p < 0.001; 35.5% vs. 83.9% p < 0.001). Both cytoplasmic and nuclear staining were no difference between the non-RT and RT groups (74.0% vs. 69.4%, p = 0.542; 22.1% vs. 35.5%, p = 0.080, respectively). So we combined the non-RT and RT group together for further analysis. Nuclear staining of FBI-1 was positively with TNM stage and distance recurrence, it showed higher expression in III+ IV stage than that in I+II stage (41.0% vs. 17.9%, p = 0.003). The patients with distance recurrence showed higher FBI-1 expression than that with no distance recurrence (39.7% vs. 19.8%, p = 0.010). In stage I, II and III patients, higher nuclear FBI-1 in primary cancer showed worse disease free survival (HR: 1.934; 95%CI: 1.055-3.579, p = 0.033) and overall survival (HR: 2.174; 95%CI: 1.102-4.290; p = 0.025) independent of gender, age, growth pattern, differentiation and RT. Conclusions: Higher nuclear FBI-1 is related with later TNM stage, distance recurrence, and worse prognosis, it can be used as a potential diagnostic and prognostic biomarker in rectal cancer.

Expression of the p73 protein in rectal cancers with or without preoperative radiotherapy

2006 ◽  
Vol 65 (4) ◽  
pp. 1143-1148 ◽  
Author(s):  
Daniella Pfeifer ◽  
Jingfang Gao ◽  
Gunnar Adell ◽  
Xiao-Feng Sun
Keyword(s):  
Preoperative Radiotherapy ◽  
Rectal Cancers

Extended lymphadenectomy and preoperative radiotherapy for lower rectal cancers

Surgery ◽  
2002 ◽  
Vol 132 (1) ◽  
pp. 27-33 ◽  
Author(s):  
Toshiaki Watanabe ◽  
Giichiro Tsurita ◽  
Tetsuichiro Muto ◽  
Toshio Sawada ◽  
Koki Sunouchi ◽  
...  
Keyword(s):  
Preoperative Radiotherapy ◽  
Extended Lymphadenectomy ◽  
Rectal Cancers

pRb2/p130 protein in relation to clinicopathological and biological variables in rectal cancers with a clinical trial of preoperative radiotherapy

2009 ◽  
Vol 24 (11) ◽  
pp. 1303-1310 ◽  
Author(s):  
Satish Babu Moparthi ◽  
Viveka Bergman ◽  
Gunnar Adell ◽  
Sten Thorstensson ◽  
Xiao-Feng Sun
Keyword(s):  
Clinical Trial ◽  
Preoperative Radiotherapy ◽  
Biological Variables ◽  
Rectal Cancers

Significance of Cox-2 expression in rectal cancers with or without preoperative radiotherapy

2005 ◽  
Vol 63 (3) ◽  
pp. 739-744 ◽  
Author(s):  
Ketevan Pachkoria ◽  
Hong Zhang ◽  
Gunnar Adell ◽  
Ingvar Jarlsfelt ◽  
Xiao-Feng Sun
Keyword(s):  
Preoperative Radiotherapy ◽  
Rectal Cancers ◽  
Cox 2
Sign in / Sign up

Export Citation Format

Share Document